Related Experiment Videos
Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children
G F A Harding1, E L Spencer, J M Wild
1Neurosciences Research Institute, Aston University, Birmingham, UK. g.f.a.harding@aston.ac.uk
Neurology
|April 24, 2002
Summary
A new visual-evoked potential (VEP) technique effectively identifies vigabatrin-associated visual field defects in children. This method is well-tolerated and accurate for young epilepsy patients unable to complete traditional perimetry.
Area of Science:
- Ophthalmology
- Neuroscience
- Pediatric Neurology
Background:
- Vigabatrin treatment in epilepsy is associated with visual field loss.
- Assessing visual field defects in young children (<9 years) is challenging with standard perimetry.
- Pediatric populations require specialized methods for visual field assessment.
Purpose of the Study:
- To develop and validate a visual-evoked potential (VEP) technique for identifying visual field defects.
- To assess the efficacy of a field-specific VEP in children with epilepsy treated with vigabatrin.
- To provide an alternative to perimetry for non-cooperative pediatric patients.
Main Methods:
- Developed a field-specific VEP using central and peripheral stimuli with varying check sizes and reversal rates.
- Recorded electroretinograms (ERG) to assess retinal function.
- Compared the diagnostic performance of the field-specific VEP with standard perimetry in 39 children (aged 3-15 years).
Main Results:
- The field-specific VEP was tolerated by 35 of 39 children.
- The VEP demonstrated a sensitivity of 75% and a specificity of 87.5% in identifying visual field defects compared to perimetry.
- Electroretinogram (ERG) 30-Hz flicker amplitude was also a useful indicator of visual field loss.
Conclusions:
- Field-specific VEPs are a well-tolerated and accurate method for children over 2 years old.
- This VEP technique is sensitive and specific for detecting vigabatrin-associated peripheral field defects.
- The VEP offers a viable alternative for visual field assessment in young children undergoing vigabatrin therapy.